🇺🇸 FDA
Pipeline program

A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma

2223-001

Phase 1 other active

Quick answer

A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma for T-cell Non-Hodgkin Lymphoma, Cutaneous T-cell lymphoma (CTCL), Peripheral T-cell lymphoma (PTCL) is a Phase 1 program (other) at Kyowa Kirin Holdings B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Kyowa Kirin Holdings B.V.
Indication
T-cell Non-Hodgkin Lymphoma, Cutaneous T-cell lymphoma (CTCL), Peripheral T-cell lymphoma (PTCL)
Phase
Phase 1
Modality
other
Status
active

Clinical trials